Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC005705 | Panoply™ Human FGF21 Knockdown Stable Cell Line | Inquiry |
| CSC-SC005705 | Panoply™ Human FGF21 Over-expressing Stable Cell Line | Inquiry |
| CSC-RT2045 | FGF21 Knockout Cell Line-HeLa | Inquiry |
| CLOE-2710 | Mouse Fgf21 (His) HEK293 Cell Lysate | Inquiry |
| CLKO-1906 | FGF21 KO Cell Lysate-HeLa | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD00334Z | FGF21 adenovirus | Inquiry |
| AD06216Z | Human FGF21 adenoviral particles | Inquiry |
| LV12842L | human FGF21 (NM_019113) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH294511 | shRNA set against Mouse FGF21 (NM_020013.4) | Inquiry |
| SHH057521 | shRNA set against Rat Fgf21(NM_130752.1) | Inquiry |
| SHH057527 | shRNA set against Mouse Fgf21(NM_020013.4) | Inquiry |
| SHH057557 | shRNA set against Human FGF21(NM_019113.2) | Inquiry |
| SHH294505 | shRNA set against Human FGF21 (NM_019113.2) | Inquiry |
| SHH294514 | shRNA set against Rat FGF21 (NM_130752.1) | Inquiry |
| SHW010196 | shRNA set against Danio rerio FGF21 (NM_001045324) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCS414961 | Human FGF21 ORF Clone (BC018404) | Inquiry |
| CDFG002294 | Human FGF21 cDNA Clone(NM_019113.2) | Inquiry |
| CDFR013923 | Rat Fgf21 cDNA Clone(NM_130752.1) | Inquiry |
| MiUTR1H-03629 | FGF21 miRNA 3'UTR clone | Inquiry |
| MiUTR1M-04692 | FGF21 miRNA 3'UTR clone | Inquiry |
| MiUTR1R-01889 | FGF21 miRNA 3'UTR clone | Inquiry |
| CDCB156540 | Canine FGF21 ORF clone (XM_541510.2) | Inquiry |
| CDCB171671 | Danio rerio FGF21 ORF Clone (NM_001045324) | Inquiry |
| CDCB184123 | Rabbit FGF21 ORF clone (XM_002723699.2) | Inquiry |
| CDCL184250 | Human FGF21 ORF clone(NM_019113.2) | Inquiry |
| CDCL184251 | Mouse FGF21 ORF clone(NM_020013.4) | Inquiry |
| CDCR380957 | Rat Fgf21 ORF Clone(NM_130752.1) | Inquiry |
Human fibroblast growth factor composited by 22 family members responsible for cell differentiation, proliferation and metabolism. As one of FGF family members, it belonged to endocrine FGF subgroup with FGF19 and FGF23. The biological activity of FGF21 working as a metabolism regulation factor has been firstly reported by Nishimura. It can promote glucose uptake of mouse 3T3-L1 adipocytes and human primary adipocytes by stimulating glucose transporter 1 gene expression. Subsequent research further confirmed that liver cell expressed FGF21 protein can significantly elevate sensitivity to insulin and shown good efficacy for blood sugar lowering and insulin sensitization. Recombinant FGF21 protein can significantly lower body weight, blood sugar and triglycerides to normal levels, thus enhancing insulin resistance and alleviating fatty liver disease in type 2 diabetes non-human primate animal model. The regulation of FGF21 on the body metabolic balance initiates by sensing nutritional status in biological state. Upregulation of FGF21 in blood induced by activating the nuclear receptor peroxisome proliferation activator receptor alpha (PPARα) signaling pathway can promote transformation of fatty acids released from the liver into ketones. In addition, activation of hypothalamus-pituitary-adrenal axis by FGF21 would accelerate corticosterone release and gluconeogenesis, thereby maintaining glucose homeostasis. Traditional FGF family members play its role by binding to FGF receptor (FGFR) with tyrosine kinase activity in cell membrane, while absence of heparin binding site make FGF21 as an endocrine factor to exert its biological effects via secretion from organ into blood. Combination of FGF21 N-terminal with FGFR upon binding in its C-terminal between a transmembrane protein called β-kloth form a stable FGF21/β-klotho/FGFR complex, which would activate downstream related molecular signals to complete its biological effect.
Although multiple protective works in metabolism of FGF21 have been found according to previous study, there is a significant elevation of FGF21 circulating levels in NAFLD patients and obesity induced fatty liver mice model.
Liver work as both endocrine and targeting organ for FGF21, early research revealed that loss of FGF21 gene can significantly increase body weight after ketogenic feeding and exacerbate steatosis by injuring ketogenic synthesis. Recent study found that recombinant FGF21 protein can inhibit the activity of mammalian target protein complex of rapamycin1 and increase hepatic insulin sensitivity. Activation of receptor γ coactivator-1α by FGF21 induced peroxisome proliferation would promote liver fatty acid oxidation.
Fig 1. Schematic summary of the pathophysiology of nonalcoholic steatohepatitis (NASH) (Manuel et al. 2020)
References: